The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Current treatment landscape of newly diagnosed multiple myeloma
In this video, Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Health, New York, NY, gives a detailed overview on the current treatment landscape of newly diagnosed multiple myeloma (MM), highlighting the variety of treatment regimens available to patients. Dr Davies mentions the data from the GRIFFIN study (NCT02874742) looking at daratumumab and the GMMG HD7 trial (NCT03617731) looking at isatuximab in the treatment of myeloma. Dr Davies then draws focus on the importance of obtaining minimal residual disease (MRD) negativity, and the promising therapeutic options available to patients in a relapsed/refractory setting, namely bispecific antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy. To conclude, Dr Davies mentions the need to further discuss management of side effects and availability of treatment in newly diagnosed myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
